Severin Schwan, Roche CEO (Sebastien Bozon/AFP via Getty Images)
Roche cuts PhII eye disease program, one day after another biotech flopped in same indication
Right after NGM failed to meet the primary endpoint in a Phase II eye disease trial, one of the Big Pharmas decided to remove a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
